News
CING
5.34
+5.74%
0.29
Weekly Report: what happened at CING last week (0727-0731)?
Weekly Report · 4d ago
Roth MKM Sticks to Their Buy Rating for Cingulate Inc (CING)
TipRanks · 07/31 15:46
Weekly Report: what happened at CING last week (0720-0724)?
Weekly Report · 07/27 10:25
Cingulate Restructures Leadership, Eliminates Chief Legal Officer
TipRanks · 07/23 20:36
Weekly Report: what happened at CING last week (0713-0717)?
Weekly Report · 07/20 10:21
Cingulate enhances equity plan and updates board leadership
TipRanks · 07/15 08:06
Weekly Report: what happened at CING last week (0706-0710)?
Weekly Report · 07/13 10:23
Weekly Report: what happened at CING last week (0629-0703)?
Weekly Report · 07/06 10:27
Cingulate Inc Added to Broad Russell 3000E Index
TipRanks · 07/02 13:30
Cingulate added to Russell 3000E Index
Seeking Alpha · 07/02 12:49
Cingulate Joins Russell 3000E Index
Benzinga · 07/02 12:30
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
Barchart · 07/02 07:30
Weekly Report: what happened at CING last week (0622-0626)?
Weekly Report · 06/29 10:22
Weekly Report: what happened at CING last week (0615-0619)?
Weekly Report · 06/22 10:31
Cingulate Gains Key U.S. Patent for Lead ADHD Drug
TipRanks · 06/16 12:46
Cingulate issues patent by USPTO for CTx-1301
TipRanks · 06/16 12:17
Weekly Report: what happened at CING last week (0608-0612)?
Weekly Report · 06/15 10:32
Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 06/09 13:39
Insider Makes Bold Move With Major Cingulate Inc. Stock Purchase
TipRanks · 06/09 02:12
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 06/08 13:52
More
Webull provides a variety of real-time CING stock news. You can receive the latest news about Cingulate Inc through multiple platforms. This information may help you make smarter investment decisions.
About CING
Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety.